| Pharmacogenetics and pharmacogenomics: recent developments, their clinical relevance and some ethical, social, and legal implications. | |
| | |
MedLine Citation:
|
PMID: 12755119 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
In recent debates on novel procedures of molecular medicine pharmacogenomics is attracting more and more attention as a genotype-based approach for improving safety and efficacy of the use of therapeutic substances. Promoted by basic knowledge generated in the field of medical genomics, facilitated by novel technological tools for mapping genetic variation in individuals, and supported by results of initial clinical studies linking specific genotypes to metabolic characteristics of individuals important for assessing drug response, procedures of pharmacogenetics and pharmacogenomics now are starting to impact significantly on clinical research and development and medical practice. In this situation assessing the goals, risk, and benefits of pharmacogenetics and pharmacogenomics is essential for the medically successful, ethically justifiable, and socially acceptable implementation of genotype-based diagnosis and pharmacotherapy. We discuss the current state of the art in pharmacogenetics and pharmacogenomics and introduce a model for evidence based assessment of its goals, risk, and benefits. We differentiate here between pragmatic and normative issues in the development of pharmacogenomics in order to contrast prevailing, insufficiently interest-based modes of public technology assessment with the evidence-based mode that can be established as part of clinical study design. Finally, we provide a framework for the analysis of social accountability that can be used for technology development and technology assessment with regard to pharmacogenomics in particular and molecular medicine in general. |
| | |
Authors:
|
Paul W Norbert; Allen D Roses |
Related Documents
:
|
3292839 - The nature of biosensor technology. 7629769 - Another weapon too far: the anti-personnel laser. 11825159 - Mobile technologies in the management of disasters: the results of a telemedicine solut... 20415589 - Microrobots for minimally invasive medicine. 11552109 - The use of capnography in the air medical environment. 14563079 - Is medical research cost effective? response to murphy and topel. 2218799 - Medical surveillance for pulmonary endpoints. 22280529 - Weight stigma, addiction, science, and the medication of fatness in mid-twentieth centu... 1348789 - Prevalence of substance use among us physicians. |
Publication Detail:
|
Type: Editorial |
Journal Detail:
|
Title: Journal of molecular medicine (Berlin, Germany) Volume: 81 ISSN: 0946-2716 ISO Abbreviation: J. Mol. Med. Publication Date: 2003 Mar |
Date Detail:
|
Created Date: 2003-05-19 Completed Date: 2004-03-12 Revised Date: 2011-07-08 |
Medline Journal Info:
|
Nlm Unique ID: 9504370 Medline TA: J Mol Med (Berl) Country: Germany |
Other Details:
|
Languages: eng Pagination: 135-40 Citation Subset: IM |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Clinical Medicine
/
economics Genotype Humans Pharmacogenetics* / ethics, legislation & jurisprudence |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Misreading the genetic blueprint: implications of genetics-based population screening.
Next Document: Organ donation: a pilot study of knowledge among medical and other university students.